The primary endpoint was complete remission from weeks 29 to 37 with minimal doses of corticosteroids Results that those on rilzabrutinib that achieved remission significantly different from placebo.
The candidate is also in phase 3 for immune thrombocytopenia, a rare blood disorder, and phase 2 for IgG4-related disease.
Sanofi is planning to start additional phase 2 studies for the candidate in immunological diseases including asthma ands atopic dermatitis this year.
Rilzabrutinib is a potential first-in-class, oral Bruton's tyrosine kinase ("BTK") inhibitor in development for immune-mediated diseases.